1.	A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO22468, 2009-012072-28, NCT01056510
2.	A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Phase: Phase IV Type: Treatment Status: Active Age: 60 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25137, NCT01283386
3.	Phase III Randomized Study of First-Line Therapy Comprising Chlorambucil Versus Fludarabine Phosphate in Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma With Villous Lymphocytes, or Non-IgM Lymphoplasmacytic Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TSH-WM1, ISRCTN56052618, TSH-WM1, NCT00608374
4.	Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WM1, NCT00566332
5.	Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: RGN0117, NCT01657955
6.	A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OMB114578, 2011-000919-22, 009988575, NCT01678430
7.	A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2) Phase: Phase III Type: Treatment Status: Active Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1115-CA, 2012-003967-23, NCT01722487
8.	Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 60 to 65 Sponsor: Other Protocol IDs: CLL0709, NCT01403246
9.	A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115601, NCT01563055
10.	A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 116586, NCT01808326
11.	This Trial is a Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: IELSG38, NCT01808599